Medexus Pharmaceuticals (TSE:MDP) Stock Price Down 6.5% – Time to Sell?

Medexus Pharmaceuticals Inc. (TSE:MDP) traded down 6.5% during trading on Tuesday . The company traded as low as C$4.39 and last traded at C$4.60. 231,189 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 152,449 shares. The stock had previously closed at C$4.92.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Stifel Nicolaus upped their price objective on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a report on Tuesday, January 14th. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Finally, Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price for the company in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a buy rating and five have given a strong buy rating to the stock. According to data from MarketBeat, Medexus Pharmaceuticals has an average rating of “Strong Buy” and a consensus price target of C$5.58.

Medexus Pharmaceuticals Price Performance

The company has a market capitalization of C$98.37 million, a price-to-earnings ratio of 80.20 and a beta of 1.96. The firm has a 50-day moving average price of C$3.30 and a two-hundred day moving average price of C$2.74.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.